2023

A strategic approach to snakebite community engagement

Lack of diagnostics helps fuel AMR

2022

Advancing family planning solutions in Burundi

Call for Action: High Time to Prioritise Health in the EU Artificial Intelligence Act

HAI is Hiring!

2021

Talking Medicine Pricing

Over 9 million people living with type 1 diabetes

European Commission is offering no meaningful solutions for equitable access

Clinical Trial Data and the Risk of Bias

Getting Hack to Reality

Health Action International successful recipients of core funding from the European AI Fund

2020

There is no UHC without Universal Medicines Coverage

HAI’s Great Health Hack Delivers Great Ideas for Access to Meds

What do the next five years have in store for the European Medicines Agency?

COVID-19 and Snakebite: Including the voices of our most marginalised

COVID-19 risks turning back the clock on years of essential development work

Reflections on the World Health Assembly

Europe’s Beating Cancer Plan

2019

Statement from the ACCISS Study regarding the WHO announcement of the first-ever insulin prequalification programme

Biased cancer drug trials are only good for one group…and it’s not patients

In Memory of Royjan Taylor

2018

HAI and Snakebite Programme Partner, James Ashe Antivenom Trust, Applaud Government Action on Antivenom at Bio-Ken Snakebite Symposium

2015

HSA4A Signs Partnership Agreement to Address Sexual and Reproductive Health and Rights in East Africa

2013

Conference contemplations: ‘Pharmaceuticals and global health – inequalities and innovation in the 21st century’

Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency

2011

Study provides recommendations on European Medicines Agency's communication on medicines

TRIPS-Plus IP demands from EU could halt South American trade deal

EU Mercosur Trade Negotiations in July

HAI Europe’s participation at the “Ad hoc meeting – Bilateral trade negotiations: State of Play”

Conflicts of interest at the European Medicines Agency (EMA) and the need for a review of staff regulations